John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Impact of IBD treatments on anti-SARS-CoV-2 immunity in Covid-19 disease or on vaccine efficacy Volume 28, supplement 5, November 2021

Figures

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4

Tables

Author
1 Laboratoire d’Immunologie, CHU Saint-Etienne, F42023 Saint-Etienne
2 CIRI – Centre International de Recherche en Infectiologie, Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, F42023 Saint-Etienne
* Correspondance

The purpose of this review is to summarize the current evidence regarding the risks and implications of Covid-19 in patients with inflammatory bowel disease (IBD) and discuss the optimal management of IBD during this pandemic. IBD patients are not at increased risk of contracting Covid-19, but several risk factors associated with severe forms have been identified, such as active IBD, obesity and corticosteroid use. Although current biotherapies used in IBD have never been associated with an increased risk of infection or severe forms of Covid-19, recent data show that the use of anti-TNF drugs may be associated with a reduced ability of treated patients to produce neutralizing antibodies against SARS-CoV-2. It also appears that patients on anti-TNF or Vedolizumab may be less susceptible to vaccination than patients on other biotherapies. However, it is strongly recommended that IBD patients be vaccinated with Covid-19 vaccines, particularly mRNA vaccines, for their greater immunogenicity. It also seems likely that adapted vaccine regimens for IBD patients will need to be considered in the future in order to maintain a good level of protection.